Indivior Pharmaceuticals Inc

Total Valuation

Indivior Pharmaceuticals Inc carries a market capitalization of 1.54B, placing it among publicly traded companies globally. Its enterprise value stands at 189.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Indivior Pharmaceuticals Inc currently has 124.77M shares outstanding.

Valuation Ratios

Indivior Pharmaceuticals Inc trades at a trailing price-to-earnings ratio of 1,482.25. The price-to-sales ratio is 161.61, and the price-to-book ratio stands at -581.99.

Enterprise Valuation

On an enterprise value basis, Indivior Pharmaceuticals Inc trades at an EV/EBITDA multiple of 435.83 and an EV/FCF ratio of 639.95. The EV/Sales ratio of 161.49 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 435.83 provides insight into valuation relative to core operating earnings.

Financial Position

Indivior Pharmaceuticals Inc maintains a current ratio of 0.90, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -141.86, indicating conservative leverage, while an interest coverage ratio of 8.70 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Indivior Pharmaceuticals Inc posts a return on equity of 1.81 and a return on invested capital of 162.80.

Taxes

Over the trailing twelve months, Indivior Pharmaceuticals Inc has paid 78.00M in income taxes, reflecting an effective tax rate of 37.50.

Stock Price Statistics

Indivior Pharmaceuticals Inc's stock has gained approximately 33.83784% over the past 52 weeks. The 50-day moving average sits at 1,021.29, while the 200-day moving average is 867.57.

Income Statement

Over the trailing twelve months, Indivior Pharmaceuticals Inc generated 1.17B in revenue and converted that into 128.00M in net income, yielding earnings per share of 1.01. EBITDA reached 435.00M, while operating income came in at 435.00M.

Balance Sheet

Indivior Pharmaceuticals Inc holds 510.00M in cash and equivalents against 366.00M in total debt, resulting in a net debt position of -184.00M. Total book value stands at -326.00M, with working capital of -105.00M providing operational flexibility.

Cash Flow

Indivior Pharmaceuticals Inc produced 218.00M in operating cash flow over the past twelve months. After subtracting -47.00M in capital expenditures, free cash flow totaled 171.00M - equivalent to 1.34 per share.

Margins

Indivior Pharmaceuticals Inc operates with a gross margin of 83.99, reflecting its pricing power and cost economics. The operating margin of 37.05 and net profit margin of 10.90 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Indivior Pharmaceuticals Inc's most recent stock split took place on October 10, 2022 with a 5:1 split ratio.

Scores

Indivior Pharmaceuticals Inc posts an Altman Z-Score of 67.91, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.